Research Summary

Clinically, I am a Molecular Pathologist focused on using advanced, cutting edge tests to drive personalized medicine in cancer diagnostics and treatment.

My lab works to understand the process of premalignant progression to invasive cancer, specifically focusing on cancers (esophageal and gastric adenocarcinoma) and pre-malignant conditions (columnar and intestinal metaplasia or Barrett’s esophagus) of the upper gastrointestinal tract as a model system.

As a disease that is often closely monitored and sampled, Barrett’s esophagus and esophageal adenocarcinoma provides an idea system to study the changes leading up to and driving invasive disease. Additionally, Barrett’s esophagus and esophageal adenocarcinoma are extremely important diseases to understand in their own as esophageal adenocarcinoma has one of the fastest rising incidences of any solid tumor and despite our understanding that it arises from a metaplastic field, we still do an extremely poor job of identifying patients early before advanced disease develops.

We have taken the approach to first understand the factors important in human tissues through advanced ‘omics’ and digital imaging approaches and then use this understanding to build model systems and functional studies. It is our goal to use the knowledge and understanding gained in these studies to develop novel biomarkers, screening strategies, and treatments to identify and treat people early before advanced disease develops.

Research Funding

  • April 15, 2016 - March 31, 2022 - Early TP53 Mutations and Genomic Doubling as a Novel Path for Barrett's Esophagus Progression , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K08DK109209


The Ohio State University, B.S,  06/2001, Chemical Engineering
The Ohio State University, Ph.D., 06/2009, Molecular Biology
The Ohio State University, M.D., 06/2009. Medicine
Brigham and Women's Hospital, 06/2011, Resident, Pathology
Harvard Medical School, 06/2012, Fellow, Molecular Genetic Pathology
Brigham and Women's Hospital, 06/2013, Resident/Gastrointestinal Pathology Fellow

Selected Publications

  1. Stachler MD, Bartlett JS. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 2006 Jun;13(11):926-31. doi: 10.1038/ PubMed PMID: 16482202.
  2. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 2006 Jul;14(1):97-106. doi: 10.1016/j.ymthe.2006.02.014. Epub 2006 Apr 19. PubMed PMID: 16624620.
  3. Stachler MD, Chen I, Ting AY, Bartlett JS. Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol Ther. 2008 Aug;16(8):1467-73. doi: 10.1038/mt.2008.129. Epub 2008 Jun 17. PubMed PMID: 18560418.
  4. Nationwide Children's Hospital, Inc., assignee. Adeno-associated virus vectors with modified capsid proteins for use as gene transfer and proliferation tools; gene therapy; genetic vaccines. United States 7749492. 2010 July.
  5. Giardino AA, Ramaiya NH, Shinagare AB, Jagannathan JP, Stachler MD, Raut CP. Case report: Calcifying fibrous tumor presenting as an asymptomatic pelvic mass. Indian J Radiol Imaging. 2011 Oct;21(4):306-8. doi: 10.4103/0971-3026.90700. PubMed PMID: 22223947; PubMed Central PMCID: PMC3249950.
  6. Cheney PP, Stachler MD, Knowles MK. Single molecule tracking of P-glycoprotein in live cells reveals dynamic heterogeneity. Conf Proc IEEE Eng Med Biol Soc. 2012;2012:3159-62. doi: 10.1109/EMBC.2012.6346635. PubMed PMID: 23366596.
  7. Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, Lencer WI, Jobin C, Blumberg RS. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013 Dec 12;39(6):1095-107. doi: 10.1016/j.immuni.2013.11.003. Epub 2013 Nov 27. PubMed PMID: 24290911; PubMed Central PMCID: PMC3902970.
  8. Kanarek N, Grivennikov SI, Leshets M, Lasry A, Alkalay I, Horwitz E, Shaul YD, Stachler M, Voronov E, Apte RN, Pagano M, Pikarsky E, Karin M, Ghosh S, Ben-Neriah Y. Critical role for IL-1β in DNA damage-induced mucositis. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E702-11. doi: 10.1073/pnas.1322691111. Epub 2014 Jan 27. PubMed PMID: 24469832; PubMed Central PMCID: PMC3926043.
  9. Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ. Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models. PLoS One. 2014;9(10):e109440. doi: 10.1371/journal.pone.0109440. eCollection 2014. PubMed PMID: 25350844; PubMed Central PMCID: PMC4211679.
  10. Baden LR, Liu J, Li H, Johnson JA, Walsh SR, Kleinjan JA, Engelson BA, Peter L, Abbink P, Milner DA Jr, Golden KL, Viani KL, Stachler MD, Chen BJ, Pau MG, Weijtens M, Carey BR, Miller CA, Swann EM, Wolff M, Loblein H, Seaman MS, Dolin R, Barouch DH. Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans. J Infect Dis. 2015 Feb 15;211(4):518-28. doi: 10.1093/infdis/jiu485. Epub 2014 Aug 26. PubMed PMID: 25165165; PubMed Central PMCID: PMC4318919.
  11. Stachler MD, Rinehart E, Lindeman N, Odze R, Srivastava A. Novel molecular insights from routine genotyping of colorectal carcinomas. Hum Pathol. 2015 Apr;46(4):507-13. doi: 10.1016/j.humpath.2015.01.005. Epub 2015 Jan 14. PubMed PMID: 25683705.
  12. Stachler M, Jia Y, Sharaf N, Wade J, Longtine J, Garcia E, Sholl LM. Filter Paper-based Nucleic Acid Storage in High-throughput Solid Tumor Genotyping. Appl Immunohistochem Mol Morphol. 2015 May-Jun;23(5):389-96. doi: 10.1097/PAI.0000000000000086. PubMed PMID: 25221956.
  13. Kaz AM, Grady WM, Stachler MD, Bass AJ. Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterol Clin North Am. 2015 Jun;44(2):473-89. doi: 10.1016/j.gtc.2015.02.015. Epub 2015 Apr 1. Review. PubMed PMID: 26021206; PubMed Central PMCID: PMC4449457.
  14. Stachler MD, Taylor-Weiner A, Peng S, McKenna A, Agoston AT, Odze RD, Davison JM, Nason KS, Loda M, Leshchiner I, Stewart C, Stojanov P, Seepo S, Lawrence MS, Ferrer-Torres D, Lin J, Chang AC, Gabriel SB, Lander ES, Beer DG, Getz G, Carter SL, Bass AJ. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Sep;47(9):1047-55. doi: 10.1038/ng.3343. Epub 2015 Jul 20. PubMed PMID: 26192918; PubMed Central PMCID: PMC4552571.
  15. Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. Cancer Immunol Res. 2015 Oct;3(10):1123-1129. doi: 10.1158/2326-6066.CIR-15-0046. Epub 2015 Jun 16. PubMed PMID: 26081225; PubMed Central PMCID: PMC4596773.
  16. Stachler MD, Rinehart EM, Garcia E, Lindeman NI. PIK3CA Mutations are Common in Many Tumor Types and are Often Associated With Other Driver Mutations. Appl Immunohistochem Mol Morphol. 2016 May-Jun;24(5):313-9. doi: 10.1097/PAI.0000000000000195. PubMed PMID: 26067136.
  17. Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ. CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma. Nat Commun. 2017 Jan 6;8:13897. doi: 10.1038/ncomms13897. PubMed PMID: 28059068; PubMed Central PMCID: PMC5227099.
  18. Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4. PubMed PMID: 28978556; PubMed Central PMCID: PMC5894850.
  19. Johncilla M, Stachler M, Misdraji J, Lisovsky M, Yozu M, Lindeman N, Lauwers GY, Odze RD, Srivastava A. Mutational landscape of goblet cell carcinoids and adenocarcinoma ex goblet cell carcinoids of the appendix is distinct from typical carcinoids and colorectal adenocarcinomas. Mod Pathol. 2018 Jun;31(6):989-996. doi: 10.1038/s41379-018-0003-0. Epub 2018 Feb 8. PubMed PMID: 29422640.
  20. Stachler MD, Camarda ND, Deitrick C, Kim A, Agoston AT, Odze RD, Hornick JL, Nag A, Thorner AR, Ducar M, Noffsinger A, Lash RH, Redston M, Carter SL, Davison JM, Bass AJ. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology. 2018 Jul;155(1):156-167. doi: 10.1053/j.gastro.2018.03.047. Epub 2018 Mar 31. PubMed PMID: 29608884; PubMed Central PMCID: PMC6035092.

Go to UCSF Profiles, powered by CTSI